Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

@article{Hammer2002DualVS,
  title={Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.},
  author={Scott M. Hammer and Florin Vaida and Kara Bennett and Mary K Holohan and Lewis B. Sheiner and Joseph J Eron and Lawrence Joseph Wheat and Ronald T. Mitsuyasu and Roy M. Gulick and Fred T. Valentine and Judith Aberg and Michael D. Rogers and Cheryl N Karol and Alfred J. Saah and Ronald H Lewis and Laura J Bessen and Carol L. Brosgart and Victor DeGruttola and John W Mellors},
  journal={JAMA},
  year={2002},
  volume={288 2},
  pages={169-80}
}
CONTEXT Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge. OBJECTIVE To assess whether adding a second PI improves antiviral efficacy of a 4-drug combination in patients with virologic failure while taking a PI-containing regimen. DESIGN Multicenter, randomized, 4-arm trial, double-blind and placebo-controlled for second PI, conducted between October 1998 and April 2000, for which there was a 24-week… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 80 references

Nonnucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short term virologic response

R Haubrich, J Whitcomb, P Keiser
Antivir Ther. 2000;5(suppl 3):S68 • 2000
View 4 Excerpts
Highly Influenced

Clinical utility of HIV-1 genotyping and expert advice. AIDS

C Tural, L Ruiz, C Holtzer
2002
View 2 Excerpts

Similar Papers

Loading similar papers…